Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
paper
Cited
Public
Unavailable
- Authors
- Gelfand, Eli V; Cannon, Christopher P
- Year
- 2006
- Journal
- Expert opinion on investigational drugs
- PMID
- 16503766
- DOI
- 10.1517/13543784.15.3.307
Rimonabant is the first selective blocker of the cannabinoid CB1 receptors being developed for the treatment of obesity, tobacco smoking and cardiometabolic risk factors. Following 1 year of treatment, rimonabant 20 mg/day leads to greater weight loss compared with placebo. Therapy with rimonabant is also associated with favourable changes in serum lipids and an improvement in glycaemic control in Type 2 diabetics. At the same dose, rimonabant significantly increases the cigarette smoking quit rates compared with placebo. Rimonabant appears to be generally well tolerated, with primary side effects of mild nausea, diarrhoea, anxiety and depression. As an agent with a novel mechanism of action, rimonabant has the potential to be a useful adjunct to lifestyle modification in the treatment of obesity, metabolic syndrome and cigarette smoking.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. | 2009 | 19016476 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease. | Rodriguez N et al. | β | 2025 | β |
| Cannabinoids and the endocannabinoid system in liver diseases. | Parfieniuk-Kowerda A et al. | β | 2024 | β |
| Evaluation of the effect of cannabidiol on the THLE-2 liver cell line exposed to lead. | Εahin S et al. | β | 2024 | β |
| Evaluation of the protective effect of cannabidiol against cadmium-induced toxicity in 2D and 3D model THLE-2 liver cell line | Εahin S et al. | β | 2024 | β |
| The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses. | Hill MN et al. | β | 2023 | β |
| Considerations for Cannabinoids in Perioperative Care by Anesthesiologists. | Laudanski K et al. | β | 2022 | β |
| Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. | Fischler PV et al. | β | 2022 | β |
| Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. | Soyka M et al. | β | 2017 | β |
| Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? | Zlebnik NE et al. | β | 2016 | β |
| Targeting Hepatic Fibrosis in Autoimmune Hepatitis. | Montano-Loza AJ et al. | β | 2016 | β |
| The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review. | Kucerova J et al. | β | 2015 | β |
| Hepatic inflammation and progressive liver fibrosis in chronic liver disease. | Czaja AJ | β | 2014 | β |
| Neuroinflammation as a possible link between cannabinoids and addiction. | Rodrigues LC et al. | β | 2014 | β |
| Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis. | Czaja AJ | β | 2014 | β |
| Rimonabant abolishes sensitivity to workload changes in a progressive ratio procedure. | Marusich JA et al. | β | 2012 | β |
| Cannabinoid type 1 receptor antagonists for smoking cessation. | Cahill K et al. | β | 2011 | β |
| Current status of novel antifibrotic therapies in patients with chronic liver disease. | Cohen-Naftaly M et al. | β | 2011 | β |
| Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration. | Basavarajappa BS et al. | β | 2009 | β |
| Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. | Agrawal A et al. | β | 2009 | β |
| Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. | Dol-Gleizes F et al. | β | 2009 | β |
| The endocannabinoid system as a target for the treatment of cannabis dependence. | Clapper JR et al. | β | 2009 | β |
| Tobacco and cannabis co-occurrence: does route of administration matter? | Agrawal A et al. | β | 2009 | β |
| Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. | Scheen AJ et al. | β | 2009 | β |
| Advances in antifibrotic therapy. | Ghiassi-Nejad Z et al. | β | 2008 | β |
| Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. | Soyka M et al. | β | 2008 | β |
| Early cannabis use and DSM-IV nicotine dependence: a twin study. | Agrawal A et al. | β | 2008 | β |
| Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. | Friedman SL | β | 2008 | β |
| Inhibitors of cannabinoid receptors and glucose metabolism. | Scheen AJ et al. | β | 2008 | β |
| Role of cannabinoid receptors in the control of gastrointestinal motility and perception. | Fioramonti J et al. | β | 2008 | β |
| Role of cannabinoids in chronic liver diseases. | Parfieniuk A et al. | β | 2008 | β |
| The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain. | Yasuno F et al. | β | 2008 | β |
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. | Soyka M et al. | β | 2008 | β |
| Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. | Bortolato M et al. | β | 2007 | β |
| Blocking the cannabinoid receptors: drug candidates and therapeutic promises. | Muccioli GG | β | 2007 | β |
| Cannabinoid-1 receptor antagonists in type-2 diabetes. | Scheen AJ | β | 2007 | β |
| Cannabinoids in health and disease. | Kogan NM et al. | β | 2007 | β |
| Drug discovery in the metabolic syndrome: context and some recent developments. | Suckling K | β | 2007 | β |
| Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. | Mangieri RA et al. | β | 2007 | β |
| GPCR structure-based virtual screening approach for CB2 antagonist search. | Chen JZ et al. | β | 2007 | β |
| Mechanisms of disease: HDL metabolism as a target for novel therapies. | Rader DJ | β | 2007 | β |
| Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. | Basavarajappa BS | β | 2007 | β |
| Opportunities and challenges for the development of pharmacological therapies for obesity treatment. | Cawthorne MA | β | 2007 | β |
| Reefer madness? Assessing the effects of cannabinoids with a less jaundiced eye. | Friedman SL | β | 2007 | β |
| Current and emerging pharmacotherapies for treating tobacco dependence. | Schnoll RA et al. | β | 2006 | β |
| Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. | Carai MA et al. | β | 2006 | β |
| Genetics of antipsychotic treatment emergent weight gain in schizophrenia. | MΓΌller DJ et al. | β | 2006 | β |
| New pharmacological approaches for the treatment of alcoholism. | Soyka M et al. | β | 2006 | β |